Corient Private Wealth
DSGN icon

Corient Private Wealth’s Design Therapeutics DSGN Stock Holding History

Corient Private Wealth’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$289K Sell
27,169
-26,761
-50% -$271K ﹤0.01% 2333
2025
Q4 		$506K Buy
+53,930
New +$422K ﹤0.01% 2304
2025
Q3 		– Sell
-26,965
Closed -$90.9K – 2592
2025
Q2 		$90.9K Hold
26,965
– – ﹤0.01% 2343
2025
Q1 		$104K Hold
26,965
– – ﹤0.01% 2169
2024
Q4 		$166K Hold
26,965
– – ﹤0.01% 2163
2024
Q3 		$145K Hold
26,965
– – ﹤0.01% 2274
2024
Q2 		$90.3K Hold
26,965
– – ﹤0.01% 2222
2024
Q1 		$109K Buy
+26,965
New +$72K ﹤0.01% 2180

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Corient Private Wealth's DSGN Position: Q1 2026 in Review

Corient Private Wealth reduced its Design Therapeutics (DSGN) stake by 50% in Q1 2026, selling an estimated $271K and leaving 27,169 shares worth $289K. The position accounts for ﹤0.01% of the portfolio, ranked #2333.

Corient Private Wealth first reported a position in DSGN in Q1 2024 and has held it in 8 quarters since. The position peaked at $506K in Q4 2025. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Corient Private Wealth held 27,169 shares of Design Therapeutics worth $289K as of Q1 2026.
  • Corient Private Wealth sold 26,761 Design Therapeutics shares in Q1 2026, an estimated $271K.
  • Design Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q1 2026, its #2333 holding.
  • Corient Private Wealth first reported a position in Design Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • Corient Private Wealth's Design Therapeutics position peaked at $506K in Q4 2025.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.